Ключевые слова
Как цитировать
Аннотация
С момента первого определения Hellman и Weichselbaum в 1995 г. концепция олигометастатического заболевания является важной областью клинической онкологии. При этом направленная на очаги метастазирования местная абляционная терапия оказалась действенной альтернативой хирургическому подходу. В то же время стереотаксическая аблятивная радиотерапия тела продемонстрировала высокий уровень достижения местного контроля над метастатическим процессом с получением повышенных результатов выживаемости больных, по сравнению с стандартным паллиативным лечением в этих условиях и, в то же время — с низким уровнем токсичности. Вместе с тем, до настоящего времени нет единого мнения относительно терапевтических и прогностических аспектов этого заболевания.
Библиографические ссылки
Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878-86. doi:10.1016/j.ijrobp.2011.08.036.
Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549-57. doi:10.1038/nrclinonc.2014.96.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8-10. doi:10.1200/JCO.1995.13.1.8.
Szturz P, Nevens D, Vermorken JB. Oligometastatic disease management: finding the sweet spot. Front Oncol. 2020;10:617793. doi:10.3389/fonc.2020.617793.
McGahan JP, van Raalte VA. History of Ablation. In: vanSonnenberg E, McMullen WN, Solbiati L, et al, eds. Tumor Ablation. 2005:3-16. doi:10.1007/0-387-28674-8.
De Ruysscher D, Wanders R, van Baardwijk A, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol. 2012;7(10):1547-55. doi:10.1097/JTO.0b013e318262caf6.
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet. 2004;363(9422):1665–72. doi:10.1016/S0140-6736(04)16250-8.
Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25(10):1954-1959. doi:10.1093/annonc/mdu370.
Engels B, Everaert H, Gevaert T, et al. Phase II study of helical tomotherapy for oligometastatic colorectal cancer. Ann Oncol. 2011;22(2):362-8. doi:10.1093/annonc/mdq385.
Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/S1470-2045(16)30532-0.
Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823-30. doi:10.1080/02841860600904854.
Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824-30. doi:10.1200/JCO.2014.56.7412.
Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601-8. doi:10.1007/s10549-008-0157-4.
Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31(4):455-60. doi:10.1016/j.urolonc.2011.02.023.
Pasqualetti F, Panichi M, Sainato A, et al. [18F] Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11:9. doi:10.1186/s13014-016-0586-x.
Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861-70. doi:10.3109/02841869509127197.
Lax I, Blomgren H, Näslund I, et al. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33(6):677-83. doi:10.3109/02841869409121782.
Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82(6):1062-70. doi:10.1002/(sici)1097-0142(19980315)82:6<1062::aid-cncr8>3.0.co;2-g.
Goto T, Hirotsu Y, Mochizuki H, et al. Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic lung cancers by genomic profile. Oncotarget. 2017;8(19):31133-31143. doi:10.18632/oncotarget.16096.
Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29(22):2972-7. doi:10.1200/JCO.2010.33.3906.
Goto T, Hirotsu Y, Mochizuki H, et al. Stepwise addition of genetic changes correlated with histological change from "well-differentiated" to "sarcomatoid" phenotypes: a case report. BMC Cancer. 2017;17(1):65. doi:10.1186/s12885-017-3059-1.
Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-37. doi:10.1016/S1470-2045(12)70510-7.
PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773-3784. doi:10.1200/JCO.20.01255.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18-e28. doi:10.1016/S1470-2045(19)30718-1.
Szturz P, Vermorken JB. Oligometastatic cancer: key concepts and research opportunities for 2021 and beyond. Cancers. 2021;13(11):2518. doi:10.3390/cancers13112518.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. The Lancet Oncology. 2020;21(1):e18-28.
Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157-166. doi:10.1016/j.radonc.2020.04.003.
Lo SS, Cardenes HR, Teh BS, et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev Anticancer Ther. 2008;8(12):1939-51. doi:10.1586/14737140.8.12.1939.
Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-6. doi:10.1001/jama.2010.261.
Boda-Heggemann J, Lohr F, Wenz F, et al. kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol. 2011;187(5):284-91. doi:10.1007/s00066-011-2236-4.
Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44-54. doi:10.1038/nrclinonc.2009.188.
Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8(2):89-91. doi:10.1016/j.ccr.2005.07.014.
Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845-1851. doi:10.1038/s41591-018-0232-2.
Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54-61. doi:10.1038/nm1523.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051-2058. doi:10.1016/S0140-6736(18)32487-5.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830-2838. doi:10.1200/JCO.20.00818.
Lehrer EJ, Singh R, Wang M, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncol. 2021;7(1):92-106. doi:10.1001/jamaoncol.2020.6146.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. doi:10.1186/s12885-019-5977-6.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2023